Mesenchymal stromal cell therapy for patients with rheumatoid arthritis.

[1]  Ridhima Vij,et al.  Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial , 2022, Stem Cell Research & Therapy.

[2]  U. Kolkundkar,et al.  Characteristics of Pooled Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) and their Potential Role in Rheumatoid Arthritis Treatment , 2022, Stem Cell Reviews and Reports.

[3]  A. Issabekova,et al.  Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis , 2021, International journal of molecular sciences.

[4]  Yeri Alice Rim,et al.  Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis , 2021, Frontiers in Immunology.

[5]  K. Tarte,et al.  Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. , 2021, Cytotherapy.

[6]  M. Lopez-Santalla,et al.  Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications , 2020, Cells.

[7]  Shigao Huang,et al.  Cervus and cucumis peptides combined umbilical cord mesenchymal stem cells therapy for rheumatoid arthritis , 2020, Medicine.

[8]  S. Zheng,et al.  Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis , 2020, Annals of the Rheumatic Diseases.

[9]  Yuelin Zhang,et al.  Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy , 2020, Cellular and Molecular Life Sciences.

[10]  Shigao Huang,et al.  Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study , 2019, Drug design, development and therapy.

[11]  M. Mohammadi,et al.  The role of BAFF and APRIL in rheumatoid arthritis , 2019, Journal of cellular physiology.

[12]  Keith J. Johnson,et al.  Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders , 2019, Clinical Rheumatology.

[13]  G. Collins,et al.  Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017 , 2019, Annals of the rheumatic diseases.

[14]  L. Abasolo,et al.  Check-control of inflammation displayed by bone marrow mesenchymal stem cells in rheumatoid arthritis patients. , 2019, Immunotherapy.

[15]  R. Perez-Fernandez,et al.  Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities , 2019, International journal of molecular sciences.

[16]  S. Zheng,et al.  Human gingival tissue-derived MSC suppress osteoclastogenesis and bone erosion via CD39-adenosine signal pathway in autoimmune arthritis , 2019, EBioMedicine.

[17]  G. Vasilev,et al.  Secretory factors produced by adipose mesenchymal stem cells downregulate Th17 and increase Treg cells in peripheral blood mononuclear cells from rheumatoid arthritis patients , 2019, Rheumatology International.

[18]  N. Rashidi,et al.  Immunomodulatory Effects of Human Adipose Tissue-derived Mesenchymal Stem Cells on T Cell Subsets in Patients with Rheumatoid Arthritis. , 2019, Iranian journal of allergy, asthma, and immunology.

[19]  R. Berebichez-Fridman,et al.  Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. , 2018, Sultan Qaboos University medical journal.

[20]  K. Kang,et al.  Intravenous Infusion of Umbilical Cord Blood‐Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial , 2018, Stem cells translational medicine.

[21]  W. Xing,et al.  Serum IFN-γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis , 2018, Journal of Translational Medicine.

[22]  S. Zheng,et al.  Role of TNF–TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications , 2018, Front. Immunol..

[23]  N. Jaroughi,et al.  Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. , 2018, Cytotherapy.

[24]  Yaoyao Chen,et al.  Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord , 2018, Scientific Reports.

[25]  Zhaohui Zheng,et al.  Loss of A20 in BM-MSCs regulates the Th17/Treg balance in Rheumatoid Arthritis , 2018, Scientific Reports.

[26]  M. Stojkovic,et al.  Ethical and Safety Issues of Stem Cell-Based Therapy , 2018, International journal of medical sciences.

[27]  R. Baharlou,et al.  Human adipose tissue‐derived mesenchymal stem cells in rheumatoid arthritis: Regulatory effects on peripheral blood mononuclear cells activation , 2017, International immunopharmacology.

[28]  Xiaoshun He,et al.  Human Gingiva-Derived Mesenchymal Stem Cells Inhibit Xeno-Graft-versus-Host Disease via CD39–CD73–Adenosine and IDO Signals , 2017, Front. Immunol..

[29]  P. Narongroeknawin,et al.  Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry , 2016, International journal of rheumatic diseases.

[30]  S. Marsal,et al.  Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial , 2016, Annals of the rheumatic diseases.

[31]  Yoshiya Tanaka.  Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. , 2015, Clinical and experimental rheumatology.

[32]  W. B. van den Berg,et al.  Novel therapeutic targets in rheumatoid arthritis. , 2015, Trends in pharmacological sciences.

[33]  Imran Ullah,et al.  Human mesenchymal stem cells - current trends and future prospective , 2015, Bioscience reports.

[34]  Yufang Shi,et al.  Immunobiology of mesenchymal stem cells , 2013, Cell Death and Differentiation.

[35]  D. Kyburz,et al.  The importance of early treatment for the prognosis of rheumatoid arthritis. , 2013, Swiss medical weekly.

[36]  E. Jones,et al.  Umbilical cord-derived stromal cell therapy for rheumatoid arthritis: what does the future hold? , 2013 .

[37]  Delin Zhu,et al.  Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. , 2013, Stem cells and development.

[38]  P. V. Schouwenburg,et al.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis , 2013, Nature Reviews Rheumatology.

[39]  Yoshiya Tanaka,et al.  [Regulation of osteoclastogenesis by human mesenchymal stem cells leading to application of a novel treatment for rheumatoid arthritis]. , 2013, Journal of UOEH.

[40]  G. Shaw,et al.  Thermoresponsive Substrates used for the Expansion of Human Mesenchymal Stem Cells and the Preservation of Immunophenotype , 2013, Stem Cell Reviews and Reports.

[41]  K. English.  Mechanisms of mesenchymal stromal cell immunomodulation , 2013, Immunology and cell biology.

[42]  Sahar M Greish,et al.  Human umbilical cord mesenchymal stem cells as treatment of adjuvant rheumatoid arthritis in a rat model. , 2012, World journal of stem cells.

[43]  F. Oliva,et al.  Biological properties of mesenchymal Stem Cells from different sources. , 2012, Muscles, ligaments and tendons journal.

[44]  B. Avalos,et al.  An Update on Stem Cell Transplantation in Autoimmune Rheumatologic Disorders , 2012, Current Allergy and Asthma Reports.

[45]  S. Zheng,et al.  Antigen-specific transforming growth factor β-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance. , 2012, Arthritis and rheumatism.

[46]  A. Tyndall.  Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases , 2012, Pediatric Research.

[47]  S. Kang,et al.  Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells , 2011, Journal of Translational Medicine.

[48]  S. Böhm,et al.  Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC , 2011, Cell Communication and Signaling.

[49]  B. Dijkmans,et al.  The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study , 2011, Annals of the rheumatic diseases.

[50]  Sanjay Kumar,et al.  Therapeutic potential of adult bone marrow‐derived mesenchymal stem cells in diseases of the skeleton , 2010, Journal of cellular biochemistry.

[51]  P. Taylor.  Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. , 2010, Current opinion in pharmacology.

[52]  M. Engelse,et al.  Isolated human islets contain a distinct population of mesenchymal stem cells , 2010, Islets.

[53]  F. Djouad,et al.  Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit? , 2009, Rheumatology.

[54]  Brian Salmons,et al.  Stem cell therapies: on track but suffer setback. , 2009, Current opinion in molecular therapeutics.

[55]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[56]  L. Isola,et al.  Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[57]  G. Dryden.  Overview of stem cell therapy for Crohn's disease , 2009, Expert opinion on biological therapy.

[58]  C. Cho,et al.  Mesenchymal stem cells overexpressing interleukin‐10 attenuate collagen‐induced arthritis in mice , 2008, Clinical and experimental immunology.

[59]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[60]  M. Dougados,et al.  Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. , 2006, Rheumatology.

[61]  R. Gay,et al.  Synovial fibroblasts: key players in rheumatoid arthritis. , 2006, Rheumatology.

[62]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[63]  L. Lagneaux,et al.  Mesenchymal Stem Cells Derived from CD133‐Positive Cells in Mobilized Peripheral Blood and Cord Blood: Proliferation, Oct4 Expression, and Plasticity , 2005, Stem cells.

[64]  H. Heinzl,et al.  Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[65]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[66]  F. Claas,et al.  Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. , 2003, Blood.

[67]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[68]  Min Zhu,et al.  Human adipose tissue is a source of multipotent stem cells. , 2002, Molecular biology of the cell.

[69]  N. Fisk,et al.  Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. , 2001, Blood.

[70]  F. Luyten,et al.  Multipotent mesenchymal stem cells from adult human synovial membrane. , 2001, Arthritis and rheumatism.

[71]  K. Satomura,et al.  Circulating Skeletal Stem Cells , 2001, The Journal of cell biology.

[72]  P. Conget,et al.  Mesenchymal progenitor cells in human umbilical cord blood , 2000, British journal of haematology.

[73]  S. Zheng,et al.  Mesenchymal stromal cells attenuate multiple sclerosis via IDO-dependent increasing the suppressive proportion of CD5+ IL-10+ B cells. , 2019, American journal of translational research.

[74]  M. Mohammadi,et al.  Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[75]  Lingyun Sun,et al.  Allogeneic mesenchymal stem cells transplantation in patients with refractory RA , 2011, Clinical Rheumatology.

[76]  T. Ichim,et al.  Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease. , 2010, Cellular immunology.

[77]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews , 2009, The Cochrane database of systematic reviews.

[78]  Zhaohui Zheng,et al.  Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. , 2008, Rheumatology.

[79]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.